Palladio Biosciences, Inc.

📍 Newtown, United States🗓 Founded 2015👥 8 employees💰 Last funded 2016
Biotechnology🌐 palladiobio.com
Website LinkedIn
Palladio Biosciences, Inc., is a private biotech company founded in 2015 to develop medicines for orphan drug diseases of the kidney. Our first product, lixivaptan, is being re-positioned for the treatment of polycystic kidney disease (PKD). PKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. It is the 4th leading cause of kidney failure and carries significant financial and emotional burden, affecting entire families. There is no cure for PKD. We are developing lixivaptan as a safe and effective agent to be used chronically to prevent the progression of PKD.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Palladio Biosciences, Inc.?
Palladio Biosciences, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Palladio Biosciences, Inc. last raise funding?
The most recent investment in Palladio Biosciences, Inc. recorded on gritt.io was in 2016.
When was Palladio Biosciences, Inc. founded?
Palladio Biosciences, Inc. was founded in 2015.
What industry is Palladio Biosciences, Inc. in?
Palladio Biosciences, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Palladio Biosciences, Inc. based?
Palladio Biosciences, Inc. is headquartered in Newtown, United States.